Current clinical treatments of AD patients use acetylcholinesterase inhibitors (AChEIs) and antagonists of N-methyl-D-aspartate receptors (NMDA) to slow down the progress of the deterioration of AD. This evidence concerns the gene ACHE and Alzheimer disease.